SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Wanwisa Dejnirattisai; Jiandong Huo; Daming Zhou; Jiří Zahradník; Piyada Supasa; Chang Liu; Helen M.E. Duyvesteyn; Helen M. Ginn; Alexander J. Mentzer; Aekkachai Tuekprakhon; Rungtiwa Nutalai; Beibei Wang; Aiste Dijokaite; Suman Khan; Ori Avinoam; Mohammad Bahar; Donal Skelly; Sandra Adele; Sile Ann Johnson; Ali Amini; Thomas G. Ritter; Chris Mason; Christina Dold; Daniel Pan; Sara Assadi; Adam Bellass; Nicola Omo-Dare; David Koeckerling; Amy Flaxman; Daniel Jenkin; Parvinder K. Aley; Merryn Voysey; Sue Ann Costa Clemens; Felipe Gomes Naveca; Valdinete Nascimento; Fernanda Nascimento; Cristiano Fernandes da Costa; Paola Cristina Resende; Alex Pauvolid-Correa; Marilda M. Siqueira; Vicky Baillie; Natali Serafin; Gaurav Kwatra; Kelly Da Silva; Shabir A. Madhi; Marta C. Nunes; Tariq Malik; Peter J.M. Openshaw; Tom Fletcher; Lorna Finch

doi:10.1016/j.cell.2021.12.046

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Wanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, Jiří Zahradník, Piyada Supasa, Chang Liu, Helen M.E. Duyvesteyn, Helen M. Ginn, Alexander J. Mentzer, Aekkachai Tuekprakhon, Rungtiwa Nutalai, Beibei Wang, Aiste Dijokaite, Suman Khan, Ori Avinoam, Mohammad Bahar, Donal Skelly, Sandra Adele, Sile Ann Johnson, Ali AminiThomas G. Ritter, Chris Mason, Christina Dold, Daniel Pan, Sara Assadi, Adam Bellass, Nicola Omo-Dare, David Koeckerling, Amy Flaxman, Daniel Jenkin, Parvinder K. Aley, Merryn Voysey, Sue Ann Costa Clemens, Felipe Gomes Naveca, Valdinete Nascimento, Fernanda Nascimento, Cristiano Fernandes da Costa, Paola Cristina Resende, Alex Pauvolid-Correa, Marilda M. Siqueira, Vicky Baillie, Natali Serafin, Gaurav Kwatra, Kelly Da Silva, Shabir A. Madhi, Marta C. Nunes, Tariq Malik, Peter J.M. Openshaw, Tom Fletcher, Lorna Finch

Liverpool School of Tropical Medicine

Research output: Contribution to journal › Article › peer-review

745 Citations (Scopus)

Abstract

On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.

Original language	English
Pages (from-to)	467-484.e15
Journal	Cell
Volume	185
Issue number	3
DOIs	https://doi.org/10.1016/j.cell.2021.12.046
Publication status	Published - 3 Feb 2022

Keywords

immune evasion
Omicron
RBD
receptor interaction
SARS-CoV-2
Spike
vaccines
variants

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cell.2021.12.046Licence: CC BY

Cite this

Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., Duyvesteyn, H. M. E., Ginn, H. M., Mentzer, A. J., Tuekprakhon, A., Nutalai, R., Wang, B., Dijokaite, A., Khan, S., Avinoam, O., Bahar, M., Skelly, D., Adele, S., Johnson, S. A., ... Finch, L. (2022). SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell, 185(3), 467-484.e15. https://doi.org/10.1016/j.cell.2021.12.046

@article{7a10b97763b449a4b9a53ede0f579808,

title = "SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses",

abstract = "On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.",

keywords = "immune evasion, Omicron, RBD, receptor interaction, SARS-CoV-2, Spike, vaccines, variants",

author = "Wanwisa Dejnirattisai and Jiandong Huo and Daming Zhou and Ji{\v r}{\'i} Zahradn{\'i}k and Piyada Supasa and Chang Liu and Duyvesteyn, \{Helen M.E.\} and Ginn, \{Helen M.\} and Mentzer, \{Alexander J.\} and Aekkachai Tuekprakhon and Rungtiwa Nutalai and Beibei Wang and Aiste Dijokaite and Suman Khan and Ori Avinoam and Mohammad Bahar and Donal Skelly and Sandra Adele and Johnson, \{Sile Ann\} and Ali Amini and Ritter, \{Thomas G.\} and Chris Mason and Christina Dold and Daniel Pan and Sara Assadi and Adam Bellass and Nicola Omo-Dare and David Koeckerling and Amy Flaxman and Daniel Jenkin and Aley, \{Parvinder K.\} and Merryn Voysey and \{Costa Clemens\}, \{Sue Ann\} and Naveca, \{Felipe Gomes\} and Valdinete Nascimento and Fernanda Nascimento and \{Fernandes da Costa\}, Cristiano and Resende, \{Paola Cristina\} and Alex Pauvolid-Correa and Siqueira, \{Marilda M.\} and Vicky Baillie and Natali Serafin and Gaurav Kwatra and \{Da Silva\}, Kelly and Madhi, \{Shabir A.\} and Nunes, \{Marta C.\} and Tariq Malik and Openshaw, \{Peter J.M.\} and Tom Fletcher and Lorna Finch",

year = "2022",

month = feb,

day = "3",

doi = "10.1016/j.cell.2021.12.046",

language = "English",

volume = "185",

pages = "467--484.e15",

journal = "Cell",

issn = "0092-8674",

publisher = "Elsevier B.V.",

number = "3",

}

Dejnirattisai, W, Huo, J, Zhou, D, Zahradník, J, Supasa, P, Liu, C, Duyvesteyn, HME, Ginn, HM, Mentzer, AJ, Tuekprakhon, A, Nutalai, R, Wang, B, Dijokaite, A, Khan, S, Avinoam, O, Bahar, M, Skelly, D, Adele, S, Johnson, SA, Amini, A, Ritter, TG, Mason, C, Dold, C, Pan, D, Assadi, S, Bellass, A, Omo-Dare, N, Koeckerling, D, Flaxman, A, Jenkin, D, Aley, PK, Voysey, M, Costa Clemens, SA, Naveca, FG, Nascimento, V, Nascimento, F, Fernandes da Costa, C, Resende, PC, Pauvolid-Correa, A, Siqueira, MM, Baillie, V, Serafin, N, Kwatra, G, Da Silva, K, Madhi, SA, Nunes, MC, Malik, T, Openshaw, PJM, Fletcher, T & Finch, L 2022, 'SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses', Cell, vol. 185, no. 3, pp. 467-484.e15. https://doi.org/10.1016/j.cell.2021.12.046

TY - JOUR

T1 - SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

AU - Dejnirattisai, Wanwisa

AU - Huo, Jiandong

AU - Zhou, Daming

AU - Zahradník, Jiří

AU - Supasa, Piyada

AU - Liu, Chang

AU - Duyvesteyn, Helen M.E.

AU - Ginn, Helen M.

AU - Mentzer, Alexander J.

AU - Tuekprakhon, Aekkachai

AU - Nutalai, Rungtiwa

AU - Wang, Beibei

AU - Dijokaite, Aiste

AU - Khan, Suman

AU - Avinoam, Ori

AU - Bahar, Mohammad

AU - Skelly, Donal

AU - Adele, Sandra

AU - Johnson, Sile Ann

AU - Amini, Ali

AU - Ritter, Thomas G.

AU - Mason, Chris

AU - Dold, Christina

AU - Pan, Daniel

AU - Assadi, Sara

AU - Bellass, Adam

AU - Omo-Dare, Nicola

AU - Koeckerling, David

AU - Flaxman, Amy

AU - Jenkin, Daniel

AU - Aley, Parvinder K.

AU - Voysey, Merryn

AU - Costa Clemens, Sue Ann

AU - Naveca, Felipe Gomes

AU - Nascimento, Valdinete

AU - Nascimento, Fernanda

AU - Fernandes da Costa, Cristiano

AU - Resende, Paola Cristina

AU - Pauvolid-Correa, Alex

AU - Siqueira, Marilda M.

AU - Baillie, Vicky

AU - Serafin, Natali

AU - Kwatra, Gaurav

AU - Da Silva, Kelly

AU - Madhi, Shabir A.

AU - Nunes, Marta C.

AU - Malik, Tariq

AU - Openshaw, Peter J.M.

AU - Fletcher, Tom

AU - Finch, Lorna

PY - 2022/2/3

Y1 - 2022/2/3

N2 - On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.

AB - On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.

KW - immune evasion

KW - Omicron

KW - RBD

KW - receptor interaction

KW - SARS-CoV-2

KW - Spike

KW - vaccines

KW - variants

U2 - 10.1016/j.cell.2021.12.046

DO - 10.1016/j.cell.2021.12.046

M3 - Article

SN - 0092-8674

VL - 185

SP - 467-484.e15

JO - Cell

JF - Cell

IS - 3

ER -

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this